Matthew Boxer has more than 18 years of experience in drug discovery and brings deep expertise in drug discovery, development, and corporate strategy. Prior to joining Cadrenal, Dr. Boxer co-founded Veralox Therapeutics in 2017 and served as Chief Operating Officer where he was responsible for corporate strategy, governance, finance, and operations. Before founding Veralox, Dr. Boxer was a co-founder and Managing Partner at Nexus Discovery Advisors, a boutique consulting firm supporting early-stage therapeutics companies navigate drug discovery, development, intellectual property strategy and fundraising. He also served as Co-Head of Translational Medicine at Inspyr Therapeutics where he led asset acquisition and development efforts. From 2010 to 2017, Dr. Boxer was a Group Leader at the National Institutes of Health (NIH), where he managed interdisciplinary teams spanning biotechnology, academia, and government. Over the course of his career, Dr. Boxer has led numerous drug discovery programs, with a particular focus on rare diseases with significant unmet clinical needs. Dr. Boxer earned a Bachelor of Science from the University of Vermont and a Ph.D. in Chemistry from the University of Chicago, where he received multiple awards for research and teaching. Following completion of his Ph.D., he undertook an NIH postdoctoral fellowship and later earned an MBA from the Johns Hopkins Carey School of Business.
